Endocrine Abstracts

Prostate carcinoma is one of the most common malignancies and the second most common cause of cancer-related deaths in men world-wide and is affected by the action of dehydrotestosteron (DHT) via androgen receptor (AR). Resveratrol as a phytochemical in grapes and red wine has diverse effects such as anti-inflammation, anti-oxidant and anti-cancer. CXCR4 as a chemokine receptor has been found to be upregulated in cancer metastasis and has been used as a prognostic marker in various types of cancer, including leukemia, breast cancer, and prostate cancer. In this study, we focused on the role of DHT in the induction of prostate cancer progression by affecting the AR and CXCR4 pathway. Also, we investigated the inhibition effect of resveratrol on DHT - induced prostate cancer metastasis. In cell viability assay, DHT increased the cell viability of LNCaP prostate cancer cell on the other hand, resveratrol and its combination with bicalutamide (BCT) as an AR-antagonist or AMD3100 as a CXCR4 inhibitor significantly reduced the cell viability promoted by DHT. Trans-well migration assay and wound healing assay represented the similar results with cell viability assay. According to the results of tunnel assay, the apoptotic activity was induced by treatment of resveratrol. As results of western blot analysis, the expression of AR, CXCR4, and the downstream genes related with epithelial-mesenchymal transition (EMT) were decreased and the expression of the apoptosis-related genes was increased by treatment of resveratrol and its combination with BCT or AMD3100. This study would suggest that resveratrol and its combination with AR and CXCR4 antagonists can be used in order to suppress the metastatic behaviors of prostate cancer.